The efficacy of combination therapy with tislelizumab and chemotherapy in the treatment of stage Ⅲb～Ⅳ non-small cell lung cancer
Objective To investigate the clinical effect of combination of tislelizumab and chemotherapy in the treatment of advanced non-small cell lung cancer(NSCLC).Methods Seventy-two patients with advanced NSCLC admitted to our hospital from February 2021 to May 2022 were selected.The patients were divided into a control group and a study group by using random number table method,36 in each group.The control group was given paclitaxel+carboplatin.The study group was given the additional treatment of tierellizumab on the basis of the control group.The short-term anti-tumor efficacy,levels of tumor markers such as squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),neuron-specific enolase(NSE)and carbohydrate antigen 125(CA125),immune function,safety and prognosis were compared between the two groups.Results The objective remission rate and clinical control rate in the study group were higher than that in the control group(P＜0.05).After treatment,the levels of SCC,CEA,NSE and CA125 in the study group were lower than those in the control group(all P＜0.001).After treatment,CD3+,CD4+and CD4+/CD8+were higherand CD8+was lower in the study group than those in the control group(all P＜0.001).The incidence of adverse drug reactions in the two groups was similar(P＞0.05).The cumulative survival rate of the study group was higher than that of the control group(P＜0.05).Conclusions Tislelizumab combined with chemotherapy can improve the clinical efficacy.It can reduce the level of tumor markers,improve the immune function and the tolerance of adverse reactions.It also improves the survival rate of patients with advanced NSCLC.
NETL
NSTL
万方数据
